A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- Sponsors Celgene Corporation
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2017 Planned End Date changed from 28 Oct 2019 to 29 Oct 2019.
- 28 Sep 2017 Planned primary completion date changed from 26 Jan 2018 to 23 Jan 2018.